<DOC>
	<DOCNO>NCT00879242</DOCNO>
	<brief_summary>This study ass safety efficacy deferasirox patient cardiac MRI T2* &lt; 20 msec .</brief_summary>
	<brief_title>Effect Deferasirox Patients With Cardiac MRI T2* &lt; 20 Msec</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>βthalassemic patient receive regular transfusion history least 20 transfusional event Patients naïve deferasirox Serum ferritin level ≥1000ng/ml ( average last 6 month assay ) ; Cardiac MRI T2* &gt; 5 &lt; 20 msec . LVEF MRI ≥56 % Patients already start deferasirox therapy Existing contraindication performance MRI procedure , include presence metallic prostheses compatible MRI procedure approve safe use MRI scanner ( e.g. , type aneurysm clip , shrapnel proximity vital organ retina ) , pacemaker , intractable claustrophobia incapability follow instruction correct performance MRI ( e.g . maintain supine position , hold breath , etc . ) Clinical condition require intensive chelate therapy basis Investigator 's judgment Stable average ALT level &gt; 300 U/L precede 12 month Uncontrolled systemic hypertension Estimated creatinine clearance &lt; 60 ml/min History nephrotic syndrome History clinically significant ocular toxicity relate chelate therapy Psychiatric disorder drug dependence might impair capability patient provide Informed Consent administer study treatment Known sensitivity study drug ( ) class study drug ( ) Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Thalassemia</keyword>
	<keyword>cardiac MRI T2*</keyword>
</DOC>